Pricing strategy (including international referencing implications) for a new orphan therapy for a neurological disorder ​

Global pricing strategy development considering the implications of international referencing for the optimal launch order sequence ​

Scope

Global (considering pricing dynamics in US, Europe and APAC)​

Therapy area

Neurological disease (orphan)​

Client

Medium-sized pharmaceutical company​​
Context

The Challenge

  • The company was developing the global launch strategy for a new therapy for the treatment of a rare (paediatric) neurological disorder​
  • The company required a detailed analysis of the pricing potential in individual markets, and the pricing/ commercial implications of potential variation in the launch order sequence (considering pricing dynamics across the US, Europe and APAC markets)​

‍

Requirements

Project Objectives

  • Assess the pricing opportunity for the new therapy for the treatment of a rare (paediatric) neurological disorder and key clinical/economic/QoL evidence requirements to support optimal pricing potential​
  • Define potential variation in pricing considering reference pricing where applicable across markets ​
  • Develop a commercial forecast framework to inform projected revenue based on credible assumptions for launch order sequence, patient population (including diagnosis rate and time to peak uptake) and potential competitor developments​

‍

Methodology

Our Approach

  • Payer primary research programme to inform the predicted list/net pricing across scope markets (and dynamics based on global pricing expectations), the minim viable/optimal evidence requirements to support reimbursement and implications for the pricing corridor​
  • Physician primary research programme to inform projected positioning in treatment/uptake​
  • Consolidation of scenarios for launch order sequencing and evidence/value demonstration to inform inputs into a commercial forecast framework​

‍

Outcomes

Value Delivered

  • The cross-functional client team received an evidence-based assessment of the predicted commercial opportunity for the new therapy across priority global markets, and strategic recommendations regarding the pricing corridor and launch order sequence to optimise revenue across global markets  ​
  • Strategic recommendations and the global commercial forecast were reviewed with the cross-functional client team to inform refinement of the evidence generation and launch strategy development ​

‍

Case Studies

Related Case Studies

Read more about our work in the field